Lysogene Appoints Chief Scientific Officer
Executive Summary
Lysogene, a biotech company specialising in the treatment of central nervous system diseases, has appointed Kimberley S. Gannon chief scientific officer. Gannon joins the business from NeuroPhage Pharmaceuticals Inc., where she was senior vice president of preclinical research and development. Prior to this, she held several leadership positions at other companies, including vice president of research and development at CereMedix, and senior director of biology at EPIX (Predix) Pharmaceuticals. Her expertise spans preclinical pharmacology, translational medicine and nonclinical drug development.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: New Hires At Everest Medicines, Arvinas, Fulcrum Therapeutics And More
Recent executive changes in the industry include seven new chief medical officers, and new chief commercial officers at Adaptimmune Therapeutics and Syndax Pharmaceuticals.